ABSTRACT. Von Hippel-Lindau (VHL) syndrome is characterized by hemangioblastomas of the brain, spinal cord, and retina, renal cysts, clear cell renal cell carcinoma, and pheochromocytoma. VHL is caused by mutations in the VHL tumor suppressor gene. We attempted to detect mutation in the VHL gene in a 5-generation Chinese family with VHL. We identified a novel small duplication that altered the reading frame downstream and created a premature TGA stop signal, resulting in severely truncated pVHL30 (p.Gly114Serfs*50) and pVHL19 (p.Gly61Serfs*50). This change was predicted to be an elongin-binding domain deletion.
INTRODUCTION
Von Hippel-Lindau disease (VHL, MIM#193300) is a rare, autosomal dominant, inherited disorder characterized by predisposition to central nervous system hemangioblastoma, retinal hemangioma, renal cysts, and clear cell renal cell carcinoma (RCC), pheochromocytoma, pancreatic cysts and neuroendocrine tumors, endolymphatic sac tumors, epididymal, and broad ligament cysts (Kaelin and Maher, 1998) . Hemangioblastomas and RCC are the 2 most common manifestations of VHL disease, occurring in up to 70-80% patients. The incidence of VHL disease is approximately 1 in 36,000 in the general population, with an overall penetrance of >90% by 65 years (Maher et al., 1991) .
Based upon clinical features of the disease, VHL disease has been divided into 2 main types based on the absence (type 1) or presence (type 2) of pheochromocytoma. Type 1 is characterized by retinal and central nervous system hemangioblastoma, renal cell carcinoma, and a low risk for pheochromocytoma, while type 2 is characterized by a high risk for pheochromocytoma. Type 2 is further subdivided into type 2A (pheochromocytoma without RCC or pancreatic cysts), 2B (pheochromocytoma with RCC or pancreatic cysts), and 2C (only pheochromocytoma) (Hes et al., 2005) .
VHL tumor suppressor gene (VHL) is the only known gene to be associated with VHL syndrome, and mutations responsible for the disease have been identified in nearly 100% of affected families (Wong et al., 2007) . Approximately 80% of individuals diagnosed with VHL disease inherited the disorder from a family member, while 20% of cases are caused by a de novo VHL mutation (Maher et al., 2011) . VHL is located on 3p25-26 and its coding sequence is present in 3 exons that encode 2 VHL proteins: a full length 213-amino acid protein (pVHL30) and a smaller protein (pVHL19) that lacks the first 53 amino acids, both of which bind to elongin B and C to inhibit the activity of the elongin complex to decrease premature transcriptional termination. Functional studies suggest that the two pVHL isoforms have equivalent effects (Schoenfeld et al., 1998; Stebbins et al., 1999) .
In this study, we identified a novel 14-base pair duplication in a large Chinese family with VHL disease. Identification of the disease-causative mutation was found to be consistent with the clinical diagnosis of VHL disease. Our results provide information that can be used in the genetic counseling of other family members.
MATERIAL AND METHODS

Patients
A family with VHL ( Figure 1 ) included more than 70 at-risk individuals over 5 generations. Symptomatic individuals received magnetic resonance imaging scans of the head and spinal cord, abdominal computed tomography scans, and examination of the retina by an ophthalmologist.
Mutation analysis
Blood samples were collected from 35 members (5 confirmed affected individuals and 1 spouse) after obtaining informed consent and approval from the Nanchang University Institutional Review Board. Genomic DNA was extracted from peripheral blood using the standard sodium dodecyl sulfate-proteinase K-phenol/chloroform method. The proband was screened for mutations in the VHL gene, including genomic DNA fragments corresponding to each exon and their flanking intronic sequences. They were amplified by polymerase chain reaction (PCR) and subjected to automatic DNA sequencing after purification. The affected allele was determined by cloning the PCR amplicon into the pMD TM 18-T vector (TaKaRa; Shiga, Japan) and then sequencing using the primers RV-M and M13-47. To confirm the pathogenicity of the variation, the amplicons of exon 1 from 34 additional family members and 70 normal controls were sequenced. Moreover, we performed 2 real-time quantitative PCR assays to determine the relative copy number of VHL. 
RESULTS
Clinical study
Eight affected individuals were retrospectively identified by reviewing medical records and from the recall of relatives. Three had passed away before 40 years of age because of central nervous system hemangioblastoma. Among the 5 living patients, 3 had renal cysts ( Figure 2 ) and 1 had developed renal cell carcinoma, 2 had central nervous system hemangioblastoma, 1 had retinal hemangioblastomas, and 1 was diagnosed with glioblastoma (Table 1 ). 
Mutation detection
We identified a novel 14-base pair duplication in exon 1 of VHL, which is predicted to result in a frameshift mutation and truncated pVHL30 (c.326-339dupTCCACAGCTACCGA, p.Gly114Serfs*50) and pVHL19 (c.167-180dupTCCACAGCTACCGA, p.Gly61Serfs*50) (Figure 3) . The relative copy number of the VHL of the proband was normal. Five affected individuals carried a heterozygous duplication; we also observed duplication in 5 asymptomatic relatives who were aged 81, 31, 16, 11, 
DISCUSSION
A wide spectrum of mutations can occur in DNA sequences, including missense mutations, nonsense mutations, microdeletions, microinsertions, splice mutations, and large deletions. According to previous studies, more than 500 mutations in VHL have been reported, with most variants unique to individual families. Approximately 72% of VHL variants are point variants or small deletions/insertions, while 28% are partial or complete deletions of the gene (Stolle et al., 1998; Hoebeeck et al., 2005; Banks et al., 2006) .
Genotype-phenotype correlations have been observed in VHL disease, revealing associations between certain variants and the risk of either pheochromocytoma or renal cell carcinoma. Truncating mutations or missense mutations that are predicted to grossly disrupt folding of the VHL protein have been associated with VHL type 1 (low risk for pheochromocytoma), and some missense mutations appear to be correlated with a specific type 2 phenotype (high risk for pheochromocytoma) (Hes et al., 2000; Wong et al., 2007; McNeill et al., 2009) . In this study, we reported a novel 14-base pair duplication mutation in a large family with VHL disease. This mutation was predicted to result in a frameshift and truncated pVHL30 and pVHL19, which causes a loss of the structural domain that interacts with elongin B and C. Sixty percent of the living patients had hemangioblastomas and renal cysts and 1 developed renal cell carcinoma. No affected individuals developed pheochromocytoma and their phenotypes were consistent with type 1. However, the relationship between a germline mutation in the VHL gene and the manifestation (age of onset and type) of VHL-related tumors is complex, and the VHL phenotype observed varies among families, although even among members of the same family, some genetic ('modifier' genes) and/or environmental factors may be involved in clinical symptoms. There is typically nearly complete penetrance by the age of 70 years (Maher et al., 1991) ; however, this family included an 81-year-old obligate heterozygote (both parent and children affected) who had no symptoms of VHL disease. To the best of our knowledge, this is the oldest asymptomatic relative identified to date; however, the individual refused to undergo screening to detect asymptomatic lesions.
Advances in understanding the genetic basis of VHL disease have facilitated diagnosis and provided insight into the biology of this disease. Molecular genetic testing for early identification of at-risk family members improves diagnostic certainty and reduces the need for costly surveillance, and eases the psychological burden of family members who have not inherited the disease-causing mutation. Surveillance of affected and asymptomatic gene carriers can reduce morbidity and mortality. In this family, we identify 5 affected and 5 asymptomatic carriers, all requiring regular clinical monitoring such as ophthalmologic screening, blood pressure measurement, audiologic evaluation, abdominal ultrasound examination, cranial computerized tomography scan, or magnetic resonance imaging.
In summary, we identified a novel small duplication resulting in severely truncated pVHL30 (p.Gly114Serfs*50) and pVHL19 (p.Gly61Serfs*50) in a large family with VHL disease. All patients and asymptomatic gene carriers require regular clinical monitoring throughout life to reduce mortality.
